GoAI
Get started
Kindstar Globalgene Technology, Inc. logo

Kindstar Globalgene Technology, Inc.

9960.HK

HKSEHealthcareMedical - Diagnostics & Research

Open in GoAI

Latest quote

HK$0.92

−HK$0.005 · -0.54%

Aug 24, 9:35 AM HKTData delayed

9960.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
CN
CEO
Shiang Huang
Listed since
Jul 16, 2021
Employees
3,100

Market position

Day range

Current HK$0.92

52-week range

Current HK$0.92

Open
HK$0.93
Previous close
HK$0.925
Volume
15.5K
0.04× average
Average volume
384.98K
Average daily volume
Market cap
950.64M HKD
Beta
0.63
Market reference 1
50-day average
HK$0.9637
-4.53% below average
200-day average
HK$1.1198
-17.84% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-13.19×
P/B (TTM)
0.3×
P/S (TTM)
0.87×
Dividend yield
10.33%

Profitability & efficiency

Gross margin
44.07%
Operating margin
-11.89%
Net margin
-6.29%

Financial health

Debt / equity
0.16×
Altman Z-score
1.14
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends73%-10%-94%-177%Gross margin, FY2021: 52.20%Gross margin, FY2022: 43.49%Gross margin, FY2023: 46.64%Gross margin, FY2024: 47.39%Gross margin, FY2025: 44.07%Operating margin, FY2021: 4.04%Operating margin, FY2022: 5.09%Operating margin, FY2023: -4.39%Operating margin, FY2024: -4.88%Operating margin, FY2025: -11.89%Net margin, FY2021: -156.28%Net margin, FY2022: 5.44%Net margin, FY2023: 4.27%Net margin, FY2024: -5.89%Net margin, FY2025: -6.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 52.20%. Gross margin FY2022 43.49%. Gross margin FY2023 46.64%. Gross margin FY2024 47.39%. Gross margin FY2025 44.07%. Operating margin FY2021 4.04%. Operating margin FY2022 5.09%. Operating margin FY2023 -4.39%. Operating margin FY2024 -4.88%. Operating margin FY2025 -11.89%. Net margin FY2021 -156.28%. Net margin FY2022 5.44%. Net margin FY2023 4.27%. Net margin FY2024 -5.89%. Net margin FY2025 -6.29%.

Income trends

Revenue

933.57M CNY+0.65%

Operating income

−111.02M CNY-145.07%

Net income

−58.74M CNY-7.61%
Income trends across reported periods1.67B CNY534.28M CNY−602.12M CNY−1.74B CNYRevenue, FY2021: 930.67M CNYRevenue, FY2022: 1.39B CNYRevenue, FY2023: 967.26M CNYRevenue, FY2024: 927.57M CNYRevenue, FY2025: 933.57M CNYOperating income, FY2021: 37.58M CNYOperating income, FY2022: 70.55M CNYOperating income, FY2023: −42.47M CNYOperating income, FY2024: −45.3M CNYOperating income, FY2025: −111.02M CNYNet income, FY2021: −1.45B CNYNet income, FY2022: 75.46M CNYNet income, FY2023: 41.29M CNYNet income, FY2024: −54.59M CNYNet income, FY2025: −58.74M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 930.67M CNY. Revenue FY2022 1.39B CNY. Revenue FY2023 967.26M CNY. Revenue FY2024 927.57M CNY. Revenue FY2025 933.57M CNY. Operating income FY2021 37.58M CNY. Operating income FY2022 70.55M CNY. Operating income FY2023 −42.47M CNY. Operating income FY2024 −45.3M CNY. Operating income FY2025 −111.02M CNY. Net income FY2021 −1.45B CNY. Net income FY2022 75.46M CNY. Net income FY2023 41.29M CNY. Net income FY2024 −54.59M CNY. Net income FY2025 −58.74M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue933.57M CNY927.57M CNY967.26M CNY1.39B CNY930.67M CNY
Cost of goods sold522.18M CNY488.01M CNY516.13M CNY783.54M CNY444.9M CNY
Gross profit411.38M CNY439.56M CNY451.13M CNY603.06M CNY485.77M CNY
Research and development95.86M CNY105.8M CNY105.34M CNY101.23M CNY90.33M CNY
Selling, general, and administrative426.54M CNY382.44M CNY413.41M CNY440.97M CNY381.82M CNY
Operating expenses522.4M CNY475.9M CNY493.6M CNY532.5M CNY448.19M CNY
Interest income62.99M CNY82.44M CNY82.83M CNY51.31M CNY12.5M CNY
Interest expense14.91M CNY11.09M CNY8.03M CNY2.52M CNY3.47M CNY
Depreciation and amortization79M CNY46.8M CNY75.03M CNY64.89M CNY57.43M CNY
Operating income−111.02M CNY−45.3M CNY−42.47M CNY70.55M CNY37.58M CNY
Net income−58.74M CNY−54.59M CNY41.29M CNY75.46M CNY−1.45B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
25%
2 beats, 6 misses, 0 met estimates
Average EPS surprise
-83.44%
8 comparable reports
Latest EPS result
-0.02
Estimate 0.05 · Miss by 153.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.10.03-0.04-0.12Q1 '23MissQ3 '23BeatQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 27, 2023: actual 0.023, estimate 0.045, surprise -50.00%, Miss. Q3 2023, reported Aug 18, 2023: actual 0.054, estimate 0.032, surprise +66.66%, Beat. Q1 2024, reported Mar 27, 2024: actual -0.008, estimate 0.044, surprise -118.61%, Miss. Q3 2024, reported Aug 28, 2024: actual 0.012, estimate 0.064, surprise -81.15%, Miss. Q1 2025, reported Mar 28, 2025: actual -0.075, estimate 0.064, surprise -217.60%, Miss. Q3 2025, reported Aug 28, 2025: actual -0.041, estimate 0.047, surprise -188.36%, Miss. Q1 2026, reported Mar 27, 2026: actual -0.024, estimate 0.046, surprise -153.45%, Miss. Q3 2026, reported Aug 26, 2026: actual —, estimate 0.047, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.23B954.75M680.95M407.16MQ1 '23BeatQ3 '23MissQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26MissQ3 '26Estimate
Q1 2023, reported Mar 27, 2023: actual 823.1M HKD, estimate 578.01M HKD, surprise +42.40%, Beat. Q3 2023, reported Aug 18, 2023: actual 532.51M HKD, estimate 570.91M HKD, surprise -6.73%, Miss. Q1 2024, reported Mar 27, 2024: actual 525.18M HKD, estimate 1.17B HKD, surprise -55.19%, Miss. Q3 2024, reported Aug 28, 2024: actual 463.81M HKD, estimate 650.46M HKD, surprise -28.70%, Miss. Q1 2025, reported Mar 28, 2025: actual 483.21M HKD, estimate 698.04M HKD, surprise -30.78%, Miss. Q3 2025, reported Aug 28, 2025: actual 499.92M HKD, estimate 616.28M HKD, surprise -18.88%, Miss. Q1 2026, reported Mar 27, 2026: actual 530.27M HKD, estimate 602.68M HKD, surprise -12.02%, Miss. Q3 2026, reported Aug 26, 2026: actual —, estimate 616.39M HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.0238

2025 complete year-16.2% since 2024

2026 partial: HK$0.095

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 9, 2026

HK$0.095

Annual

Record Jun 11, 2026 · Payment Aug 27, 2026

Dividend

Ex-dividend Jun 9, 2025

HK$0.0238

Annual

Record Jun 10, 2025 · Payment Aug 27, 2025

Dividend

Ex-dividend Jun 7, 2024

HK$0.0284

Annual

Record Jun 11, 2024 · Payment Aug 29, 2024

9960.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 9960.HK

research.disclaimer